"Royalty Pharma delivered strong performance in 2022," said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. "We reported impressive growth and deployed substantial capital in value-enhancing transactions, further strengthening our leadership position in funding life science innovation. We expanded our talented team to support our robust deal pipeline and our substantial growth opportunities. With strong fundamental tailwinds underpinning our business, we expect to deliver attractive, long-term compounding growth while transforming patient lives."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RPRX:
- Royalty Pharma Reports Q4 and Full Year 2022 Results
- Royalty Pharma to Present at Upcoming Investor Conferences
- Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
- Royalty Pharma provides business update, outlook
- Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
